Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

Exclusion criteria

• ✕. Any of the following conditions:
• ✕. Acute promyelocytic leukemia (APL);
• ✕. Central nervous system leukemia (CNSL);
• ✕. AML secondary to chemotherapy/radiotherapy for other malignancies or antecedent hematological disorders (e.g., MDS, MPN, CML);
• ✕. Prior treatment with hypomethylating agents (HMA) or venetoclax;
• ✕. Prior anti-AML therapy (except for leukocytosis management such as hydroxyurea or leukapheresis);
• ✕. History of other malignancies within the past 5 years (except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, or other malignancies that have been effectively controlled without treatment in the past five years);
• ✕. Inability to take oral medication or malabsorption syndrome;